UPDATE 1-Germany's Merck to buy Bio-Techne for $11.3 billion

Bio-Techne Corporation
Merck & Co., Inc.

Bio-Techne Corporation

TECH

0.00

Merck & Co., Inc.

MRK

0.00

Adds shares in paragraph 2, details in paragraphs 3 to 5

June 25 (Reuters) - Merck KGaA MRCG.DE has agreed to acquire biotech firm Bio-Techne Corp TECH.O for $11.3 billion, the German science and healthcare firm said in a statement on Thursday.

Shares of Bio-Techne rose 22% in premarket trading.

The offer price of $73 per share implies a 24% premium to Bio-Techne's close on Wednesday.

The acquisition would expand Merck's presence in life-science research. Bio-Techne supplies research reagents, proteins, antibodies, analytical instruments and other tools used by scientists and drug developers.

The German firm said it would fund the acquisition through a combination of existing cash and new debt.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.